Month: April 2026

Virtuix Secures 26th Patent, Reinforcing Leadership in 360-Degree Movement Technology

Written by Customer Service on April 30, 2026. Posted in Public Companies.

Expanding Patent Portfolio Builds Competitive Moat Across Consumer Gaming, Enterprise, and Defense Markets AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) — Virtuix Inc. (NASDAQ: VTIX), a leading developer of full-body virtual reality (VR) systems, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 26th U.S. patent, covering proprietary innovations in the mechanical design of its latest Omni One omni-directional treadmill. The newly allowed patent reinforces Virtuix’s leadership position in full-body movement technology and expands the company’s intellectual property moat around Omni One, its most advanced platform to date that enables users to physically walk, run, crouch, and jump in 360 degrees within virtual environments. The platform has received industry...

U.S. Consumer Credit Market Increasingly Splitting Along a K-Shaped Path, TransUnion Research Finds

Written by Customer Service on April 30, 2026. Posted in Public Companies.

As super prime ranks grow, non-prime consumers face mounting debt pressures CHICAGO, April 30, 2026 (GLOBE NEWSWIRE) — New TransUnion (NYSE: TRU) research confirms that the U.S. consumer credit market is increasingly splitting along a K‑shaped path, with the riskiest and least risky credit tiers experiencing the most pronounced shifts in credit use. While credit conditions have remained stable overall, and improved for a large segment of consumers, others are struggling in the face of rising expenses and increasing debt. TransUnion released the research in conjunction with its Q1 2026 Credit Industry Insights Report (CIIR). As the divergence between super prime and non-prime consumers becomes more pronounced, it is unfolding differently across the credit spectrum. At the top, the super prime segment continues to expand, with the...

Kadant Completes Acquisition of voestalpine BÖHLER Profil

Written by Customer Service on April 30, 2026. Posted in Mergers And Acquisitions.

WESTFORD, Mass., April 30, 2026 (GLOBE NEWSWIRE) — Kadant Inc. (NYSE: KAI) has completed its previously announced acquisition of voestalpine BÖHLER Profil GmbH & Co KG and voestalpine BÖHLER Profil VerwaltungsGmbH. At closing, the company names were changed to Kadant Profil GmbH & Co KG and Kadant Profil Verwaltungs GmbH (collectively, Kadant Profil). The company will continue to operate in its current location in Bruckbach, Austria, as part of Kadant’s Industrial Processing reporting segment. Founded in 1872, Kadant Profil is a manufacturer of customized rolled profiles and industrial knife solutions for demanding industrial applications. A market leader in high-quality profiles, the company specializes in near-net-shape rolling and advanced materials to produce application-specific solutions. Kadant Profil is recognized...

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

Written by Customer Service on April 30, 2026. Posted in Earnings Releases And Operating Results.

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significantly accelerate development progress of NCEL-101 and rest of clinical pipeline in 2026 ZURICH, Switzerland, April 30, 2026 (GLOBE NEWSWIRE) — NewcelX...

Lerøy Seafood Group ASA: Notice of Annual General Meeting

Written by Customer Service on April 30, 2026. Posted in Public Companies.

The Annual General Meeting of Lerøy Seafood Group ASA will be held on 27 May 2026 at 10:00 (CEST) as a digital meeting. The notice of the Annual General Meeting, including the agenda and related information on participation, advance voting and proxy, is enclosed. The notice and the associated attachments are also available on the Company’s website: https://www.leroyseafood.com/en/investor/corporate-governance/generalmeetings/ This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.AttachmentLSG-Notice-of-annual-general-meeting

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

Written by Customer Service on April 30, 2026. Posted in Public Companies.

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its Board of Directors. “We are pleased to nominate Lykke to our Board of Directors,” said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics. “Her extensive experience in global drug development and broad perspective across therapeutic areas will complement the expertise of our Board. As we continue to advance our pipeline and strategy, her insights will be valuable in supporting ProQR’s...

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Written by Customer Service on April 30, 2026. Posted in Public Companies.

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in adults determined to be at high risk for mpox infection. The expanded indication in Singapore is supported by existing human safety data and data from a well-controlled animal study in which ACAM2000® vaccine was shown to be effective in protecting against mpox virus exposure. This regulatory milestone expands the authorized use of ACAM2000® in Singapore to support public health preparedness and response efforts. “The Singapore HSA approval of ACAM2000® for immunization against mpox in high-risk individuals demonstrates the strength and breadth...

MoneyHero Group Reports Unaudited Fourth Quarter and Audited Full Year 2025 Results

Written by Customer Service on April 30, 2026. Posted in Earnings Releases And Operating Results.

Delivery of first quarterly profitability: Attained Q4 2025 net profit of US$0.5 million and first-ever Adjusted EBITDA1 gain since listing of US$0.7 million, driven by structurally lower costs and accelerating higher-margin revenue mix Structural cost reductions with strong top-line growth: Total operating costs and expenses for the quarter decreased 15% year-over-year to US$21.4 million while revenue increased 27% year-over-year to US$20.0 millionSINGAPORE, April 30, 2026 (GLOBE NEWSWIRE) — MoneyHero Limited (Nasdaq: MNY) (“MoneyHero” or the “Company”), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced its financial results for the fourth quarter and full year ended December 31, 2025. Management Commentary: Danny...

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

Written by Customer Service on April 30, 2026. Posted in Public Companies.

PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its first quarter 2026 financial results and business update after the market closes on Thursday, May 7, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will be available on the BridgeBio website for 30 days following the event. Participants may access the webcast by registering...

Ealixir Launches Beta of RepuTrust, an AI-Powered Digital Identity Platform, Granting Early Access to Our Select Users

Written by Customer Service on April 30, 2026. Posted in Public Companies.

Introducing a New Way to Measure and Understand Online Reputation, Powered by ReputScore — Ealixir’s Proprietary AI-Driven Reputation Metric MIAMI, Fla., April 30, 2026 (GLOBE NEWSWIRE) — Ealixir Inc. (OTCID: EAXR) (“Ealixir” or the “Company”), a digital identity infrastructure company specializing in online reputation management, today announced the beta launch of RepuTrust, its AI-powered digital identity platform. Beginning today, select users will receive early access to the RepuTrust platform, powered by an AI-driven engine that searches, analyzes, and scores online content. RepuTrust builds on the development of ReputScore, originally introduced as a standalone application designed to analyze the global digital footprint of individuals and generate a score of 1 to 100. We have since evolved ReputScore into a proprietary...

Month: April 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals